Pelthos Therapeutics Inc. held its 2026 Annual Meeting of Stockholders on September 29, 2026. During the meeting, stockholders voted on three proposals, including the election of directors, the ratification of an independent auditor, and the approval of a new equity incentive plan.
The company reported that as of the close of business on August 4, 2026, there were 3,828,469 shares of common stock and 52,128 shares of Series A Preferred Stock issued and outstanding. Stockholders as of the record date were entitled to one vote per share of common stock and one vote per share of common stock underlying the Series A Preferred Stock on an "as converted" basis.
At the meeting, a total of 3,396,094 votes were cast, representing 70.0% of the voting power of all issued and outstanding shares, constituting a quorum.
The first proposal was the election of eight directors to serve until the 2027 Annual Meeting or until their successors are elected. The nominees were elected by a vote of 2,866,344 for Peter Greenleaf, 2,882,376 for Richard Baxter, 2,878,889 for Todd Davis, 2,885,576 for Andrew Einhorn, 2,884,226 for Ezra Friedberg, 2,883,783 for Dr. Richard Malamut, 2,775,221 for Matthew Pauls, and 2,885,576 for Scott Plesha.
The second proposal was the ratification of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The ratification received 3,394,740 votes for, 1 vote against, and 1,353 abstentions.
The third proposal was the approval of the Pelthos Therapeutics Inc. 2026 Equity Incentive Plan (the "2026 Plan"). The plan was approved by a vote of 2,698,543 for, 187,365 against, and 13 abstentions. The 2026 Plan replaces the Pelthos Therapeutics Inc. 2023 Equity Incentive Plan, as amended and restated, and became effective immediately upon stockholder approval. The plan is filed as Exhibit 10.1 to this Current Report on Form 8-K.
